Published in Clin Epidemiol on May 26, 2016
Cost-Effectiveness of Drug Treatments for Advanced Melanoma: A Systematic Literature Review. Pharmacoeconomics (2017) 0.75
Cudraflavone C Induces Apoptosis of A375.S2 Melanoma Cells through Mitochondrial ROS Production and MAPK Activation. Int J Mol Sci (2017) 0.75
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med (2009) 65.36
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Cancer statistics, 2006. CA Cancer J Clin (2006) 30.71
Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-99: results of the EUROCARE-4 study. Lancet Oncol (2007) 9.57
The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med (1985) 8.55
The Danish Cancer Registry--history, content, quality and use. Dan Med Bull (1997) 6.07
EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary. Eur J Cancer (2009) 5.61
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. J Clin Oncol (2015) 5.49
Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE--5-a population-based study. Lancet Oncol (2013) 5.04
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol (2015) 2.80
Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. J Clin Oncol (2012) 2.42
Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial. Lancet Oncol (2011) 2.32
2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: a randomised, multicentre trial. Lancet (2011) 2.24
International trends in the incidence of malignant melanoma 1953-2008--are recent generations at higher or lower risk? Int J Cancer (2012) 2.07
Melanoma incidence and mortality in Europe: new estimates, persistent disparities. Br J Dermatol (2012) 1.83
Sentinel and nonsentinel node status in stage IB and II melanoma patients: two-step prognostic indicators of survival. J Clin Oncol (2006) 1.75
Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: results from a single-institution hospital-based observational cohort study. Ann Oncol (2009) 1.55
Comparison of classification systems in melanoma sentinel lymph nodes--an analysis of 697 patients from a single center. Cancer (2010) 1.42
Sentinel lymph node biopsy and survival in elderly patients with cutaneous melanoma. Br J Surg (2011) 1.40
Clinical considerations on sentinel node biopsy in melanoma from an Italian multicentric study on 1,313 patients (SOLISM-IMI). Ann Surg Oncol (2009) 1.36
Survival analysis and clinicopathological factors associated with false-negative sentinel lymph node biopsy findings in patients with cutaneous melanoma. Ann Surg Oncol (2006) 1.04
Melanoma of unknown primary origin: a population-based study in the Netherlands. Eur J Cancer (2012) 1.03
Melanoma without a detectable primary site with metastases to lymph nodes. Dermatol Surg (2010) 0.96
Association of socioeconomic status with Breslow thickness and disease-free and overall survival in stage I-II primary cutaneous melanoma. Mayo Clin Proc (2011) 0.94
Malignant melanoma of the skin: long-term follow-up and time to first recurrence. World J Surg (2011) 0.91
Metastatic melanoma: the new era of targeted therapy. Expert Opin Ther Targets (2012) 0.90
Prognostic factors associated with sentinel lymph node positivity and effect of sentinel status on survival: an analysis of 1049 patients with cutaneous melanoma. Melanoma Res (2010) 0.89
Monitoring stage-specific trends in melanoma incidence across Europe reveals the need for more complete information on diagnostic characteristics. Eur J Cancer Prev (2004) 0.89
Long-term follow-up reveals that ulceration and sentinel lymph node status are the strongest predictors for survival in patients with primary cutaneous melanoma. Eur J Surg Oncol (2011) 0.89
Sentinel lymph node biopsy in melanoma: a micromorphometric study relating to prognosis and completion lymph node dissection. Br J Dermatol (2007) 0.88
Incidence and survival in patients with cutaneous melanoma by morphology, anatomical site and TNM stage: a Danish Population-based Register Study 1989-2011. Cancer Epidemiol (2014) 0.86
Survival of patients with skin melanoma in Europe increases further: Results of the EUROCARE-5 study. Eur J Cancer (2015) 0.85
Value of sentinel node status as a prognostic factor in melanoma: prospective observational study. BMJ (2006) 0.84
Clinical characteristics, management and survival in young adults diagnosed with malignant melanoma: A population-based cohort study. Acta Oncol (2013) 0.83
Up-to-date results on survival of patients with melanoma in Germany. Br J Dermatol (2012) 0.81
Low level of education is associated with later stage at diagnosis and reduced survival in cutaneous malignant melanoma: a nationwide population-based study in Sweden. Eur J Cancer (2013) 0.80
BRAFV600E protein expression in primary cutaneous malignant melanomas and paired metastases. JAMA Dermatol (2015) 0.83
Systematic review and meta-analysis on the proportion of patients with breast cancer who develop bone metastases. Crit Rev Oncol Hematol (2017) 0.75
Estimating the cure proportion of malignant melanoma, an alternative approach to assess long term survival: a population-based study. Cancer Epidemiol (2014) 0.75